Dyax Corp. (NASDAQ: DYAX) is focused on discovering, developing, and commercializing novel biopharmaceuticals for medical needs that are currently unmet. The company hopes to meet its objectives while delivering outstanding value to patients and stockholders. Their produce candidates include fully human monoclonal antibodies in addition to small proteins and peptides. For further information, visit the Company’s web site at www.dyax.com.
- 17 years ago
QualityStocks
Dyax Corp. (NASDAQ: DYAX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…